Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Institut du Cancer de Montpellier - Val d'Aurelle
Eligible patients are randomly allocated to receive either bevacizumab with raltitrexed and oxaliplatin combination or bevacizumab with FOLFOX 6 combination. Random allocation schedule is performed using a minimization technique for the following stratification factors: * Center * Number of metastatic sites: 1 versus \> 1 * Bevacizumab-based first-line therapy: Yes versus No
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted